Compare Incyte Corporation (INCY) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.37. The key difference: Incyte Corporation is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| INCY | QDTY | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $118.52 | $46.71 |
52-Week Low | $67.38 | $36.57 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QDTY trades at $39.53 with minimal daily movement (+0.15%). The stock demonstrates consistent dividend distributions with weekly payouts ranging from $0.22 to $0.32 per share throughout 2026. Technical indicators show stable price action while fundamental metrics remain undisclosed in available data. Recent corporate actions focus exclusively on dividend distributions with no significant business developments reported.
The outlook for QDTY appears income-focused given the regular dividend schedule, though fundamental analysis is limited by missing financial ratios. Key risks include dependency on dividend sustainability and potential market volatility. Investment appeal centers on yield generation rather than growth prospects, requiring careful monitoring of underlying financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
